November 07, 2017
Article
FDA officials discuss safety data and drug approvals at the American College of Rheumatology Annual Meeting.
A significant portion of patients with rheumatoid arthritis may develop cardiovascular disease.
With the growing use of cancer immunotherapies, rheumatologists expect to see more cases of inflammatory conditions.
Patients with osteoarthritis may be able to receive targeted therapy based on phenotypes.
Major adverse cardiovascular event rates for baricitinib stabilize over time.
Methotrexate discontinuation was not observed to impact rheumatoid arthritis treatment with tocilizumab, according to an abstract presented at the 2017 American College of Rheumatology Annual Meeting.
November 06, 2017
Some patients with rheumatoid arthritis require a refined treat-to-target plan.
Low incidence of 14-3-3η in patients with long-term RA, chronic HCV with arthralgias.
Treatment for psoriatic arthritis may impact symptoms and patient-reported outcomes.
November 04, 2017
Flares and immune-related adverse events are common among patients with rheumatologic diseases but can often be successfully managed.
